Edge is developing novel and proprietary microparticle formulations of known active drugs that deliver optimal concentrations, sustained for the required time towards achieving life-saving therapeutic activity in the brain. The technology can be scaled up for commercial production, has ideal handling characteristics, and is simple to prepare and administer so as to not interfere with surgery work flow. The unique formulation, along with the technology to manufacture it, is consistent with regulatory requirements.